12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Arzerra ofatumumab regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending against the use of Arzerra ofatumumab from GlaxoSmithKline and Genmab to treat chronic lymphocytic...

Read the full 98 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >